GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-2439821 | LY2439821 | Taltz®
ixekizumab is an approved drug (FDA & EMA (2016))
Compound class:
Antibody
Comment: Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 [1]. In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. EU EMA (2016) | US FDA (2016) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9467 | ixekizumab |
Synonyms ![]() |
| LY-2439821 | LY2439821 | Taltz® |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 380 |
| Other databases | |
| GtoPdb PubChem SID | 187051842 |
| PubChem SID | 187051842 |
| Search PubMed clinical trials | ixekizumab |
| Search PubMed titles | ixekizumab |
| Search PubMed titles/abstracts | ixekizumab |
| Wikipedia | Ixekizumab |